$-0.05
(Market cap
$16 Mln
Recently Viewed
Clear AllMarket cap
$16 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
227.7
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-7.4 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
36,281,252
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
JUPITER NEUROSCIENCES INC (JUNS)
| -61.2 | -4.7 | -57.7 | -38.1 | -- | -- | -- |
|
BSE Sensex
| -8.3 | 4.2 | -5.6 | -2.4 | 9.2 | 10.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
|---|---|
|
JUPITER NEUROSCIENCES INC (JUNS)
| -90.5 |
|
S&P Small-Cap 600
| 4.0 |
|
BSE Sensex
| 9.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
JUPITER NEUROSCIENCES INC (JUNS)
|
0.4 | 15.9 | 0.0 | -9.7 | -5,195.6 | -- | -- | 227.7 |
| 4.0 | 455.5 | 73.2 | -67.8 | -82.1 | -65.5 | -- | 5.9 | |
| 19.5 | 1,263.0 | 0.0 | -147.4 | -29,734.7 | -150.3 | -- | 7.5 | |
| 14.0 | 2,706.5 | 550.0 | 458.1 | -3.3 | 45.9 | 5.9 | 2.2 | |
| 5.3 | 1,177.4 | 4.5 | -340.2 | -518.6 | 501.4 | -- | 2.1 | |
| 15.6 | 2,154.2 | 17.2 | -102.1 | -363.1 | -19 | -- | 3.7 | |
| 16.8 | 1,224.6 | 403.3 | 22.8 | 3,081.6 | 9.1 | 433.5 | 4.4 | |
| 3.9 | 687.9 | 4.6 | -201.1 | -4,342.4 | -146.8 | -- | 5.7 | |
| 17.9 | 445.5 | 4.8 | 53.5 | -- | 12.2 | 10.8 | 1.2 | |
| 21.9 | 2,732.0 | 460.2 | -175.5 | -37.7 | -22.6 | -- | 3.8 |
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of... Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer's disease. It is also involved in the development of JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, the company develops JNS115, which is in Phase IIa trial for the treatment of Parkinson's disease. It has a strategic partnership with Zina Biopharmaceuticals, LLC to advance Phase 2a clinical trial to evaluate the safety, tolerability, and pharmacokinetics of Resveratrol (JOTROLTM) in individuals with Parkinson's disease; and with Aquanova AG to develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida. Read more
Co-Founder, CEO & Chairman of the Board
Mr. Christer Rosen
Co-Founder, CEO & Chairman of the Board
Mr. Christer Rosen
Headquarters
Jupiter, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of JUPITER NEUROSCIENCES INC (JUNS) is $0.40 (NASDAQ) as of 23-Apr-2026 11:33 EDT. JUPITER NEUROSCIENCES INC (JUNS) has given a return of -38.14% in the last 1 years.
Since, TTM earnings of JUPITER NEUROSCIENCES INC (JUNS) is negative, P/E ratio is not available.
The P/B ratio of JUPITER NEUROSCIENCES INC (JUNS) is 227.66 times as on 17-Apr-2026, a 3887 premium to its peers’ median range of 5.71 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-4.13
|
-19.49
|
|
2024
|
-127.19
|
74.38
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of JUPITER NEUROSCIENCES INC (JUNS) are Rs 3.33 and Rs 0.31 as of 23-Apr-2026.
JUPITER NEUROSCIENCES INC (JUNS) has a market capitalisation of $ 16 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in JUPITER NEUROSCIENCES INC (JUNS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.